| Previous close | 60.00 |
| Open | 60.00 |
| Bid | 92.90 |
| Ask | 100.10 |
| Strike | 70.00 |
| Expiry date | 2022-08-19 |
| Day's range | 60.00 - 60.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Motley Fool
Here's How This Beaten-Down Stock Could 10X by 2024
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
- Yahoo Finance
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
- Yahoo Finance
Novavax does not have a forecast for U.S. orders in 2022: CEO Erck
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
© 2022 Yahoo. All rights reserved.
